Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. (23rd January 2014)

• Record Type: Journal Article
• Authors: Wu, Hua-Hsi; Lin, Wen-chang; Tsai, Kuo-Wang
• Is Part Of: Expert reviews in molecular medicine. Volume 16(2014)
• Publication Date: 2014-01-23
• Subjects: Molecular biology -- Periodicals; 616.042
• DOI: 10.1017/erm.2013.16
• Languages: English
• ISSNs: 1462-3994

Abstract

Abstract : Carcinoma of the stomach is one of the most prevalent cancer types in the world. Although the incidence of gastric cancer is declining, the outcomes of gastric cancer patients remain dismal because of the lack of effective biomarkers to detect early gastric cancer. Modern biomedical research has explored many potential gastric cancer biomarker genes by utilising serum protein antigens, oncogenic genes or gene families through improving molecular biological technologies, such as microarray, RNA-Seq and the like. Recently, the small noncoding microRNAs (miRNAs) have been suggested to be critical regulators in the oncogenesis pathways and to serve as useful clinical biomarkers. This new class of biomarkers is emerging as a novel molecule for cancer diagnosis and prognosis, including gastric cancer. By translational suppression of target genes, miRNAs play a significant role in the gastric cancer cell physiology and tumour progression. There are potential implications of previously discovered gastric cancer molecular biomarkers and their expression modulations by respective miRNAs. Therefore, many miRNAs are found to play oncogenic roles or tumour-suppressing functions in human cancers. With the surprising stability of miRNAs in tissues, serum or other body fluids, miRNAs have emerged as a new type of cancer biomarker with immeasurable clinical potential.